Hospital
Regions Hospital
Regions Hospital was paid $44.39M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99285, emergency room visit (most serious) — 35% of everything it billed.
33Billing provider infoREGIONS HOSPITAL
SAINT PAUL, MN 55101
SAINT PAUL, MN 55101
33aNPI1629006457assigned 06/29/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$44.39M
24GClaims431,595
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Minnesota
Rank by total paid#2 of 5
Median peer was paid$17.26M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,604 | $3.50M | |
| 2019 | 54,052 | $5.58M | |
| 2020 | 40,527 | $4.36M | |
| 2021 | 81,748 | $7.43M | |
| 2022 | 71,420 | $7.98M | |
| 2023 | 73,178 | $8.66M | |
| 2024incomplete | 51,066 | $6.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 35% | 40,197 | 37,313 | $15.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 56,651 | 52,747 | $13.91M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 43,720 | 41,058 | $7.42M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.5% | 23,995 | 19,746 | $1.99M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 13,715 | 12,569 | $1.61M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.2% | 1,685 | 189 | $529K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,651 | 27,015 | $336K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,748 | 2,639 | $296K |
| G0378 | Hospital observation service, per hour | <1% | 2,101 | 1,407 | $274K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,438 | 5,804 | $255K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,023 | 675 | $245K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 42,480 | 36,933 | $175K |
100 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,445 | $147K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,434 | $145K |
| 93296 | <1% | 4,712 | $122K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,140 | $97K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,628 | $86K |
| 80053 | Comprehensive metabolic panel | <1% | 6,678 | $85K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 820 | $77K |
| 0002A | <1% | 3,178 | $66K | |
| 77336 | <1% | 624 | $62K | |
| 0001A | <1% | 3,529 | $60K | |
| 93798 | <1% | 444 | $50K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 135 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,746 | $42K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,824 | $40K |
| 16020 | <1% | 492 | $37K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 421 | $37K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,019 | $36K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,062 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,089 | $27K |
| 77412 | <1% | 114 | $25K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,544 | $24K |
| 85027 | <1% | 47,279 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 441 | $21K |
| 36591 | <1% | 1,119 | $20K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 602 | $20K |
| 91200 | <1% | 341 | $19K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,751 | $19K |
| 36000 | <1% | 2,822 | $18K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,756 | $17K |
| 84484 | <1% | 8,326 | $16K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 45 | $16K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 335 | $16K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 41 | $12K |
| 82947 | <1% | 1,750 | $11K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 416 | $10K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 141 | $9K |
| 82962 | <1% | 3,156 | $8K | |
| 81001 | <1% | 9,780 | $7K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 352 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 230 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 320 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 25 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 83 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,984 | $5K |
| 94726 | <1% | 78 | $4K | |
| 82248 | <1% | 5,837 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 42 | $3K |
| 85610 | <1% | 1,302 | $3K | |
| 71250 | <1% | 29 | $2K | |
| 80076 | <1% | 1,501 | $2K | |
| 83735 | <1% | 1,180 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 186 | $2K |
| 83690 | <1% | 1,413 | $2K | |
| 93299 | <1% | 84 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 167 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 60 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 76376 | <1% | 24 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,865 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,766 | $1K |
| 99152 | <1% | 158 | $874.61 | |
| 87634 | <1% | 135 | $656.33 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 158 | $502.44 |
| 94729 | <1% | 145 | $470.38 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 733 | $440.32 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $403.76 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,071 | $362.34 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $354.96 |
| 82728 | <1% | 27 | $354.12 | |
| 93226 | <1% | 28 | $350.92 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,084 | $347.77 |
| 83605 | <1% | 143 | $312.10 | |
| 83880 | <1% | 92 | $285.63 | |
| 81025 | <1% | 483 | $234.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,194 | $196.38 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27 | $180.21 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27 | $132.60 |
| 84100 | <1% | 25 | $99.04 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15 | $94.92 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 98 | $93.93 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 15 | $93.53 |
| C1769 | Guide wire | <1% | 14 | $76.49 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 136 | $52.17 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 25 | $46.20 |
| 36416 | <1% | 228 | $43.45 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 27 | $42.69 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 201 | $28.94 |
| 82077 | <1% | 43 | $27.64 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 221 | $27.60 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 123 | $25.27 |
| A0425 | Ground mileage, per statute mile | <1% | 25 | $20.05 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 50 | $15.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 124 | $13.70 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 293 | $9.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 55 | $5.18 |
| 82565 | <1% | 12 | $2.24 | |
| A9270 | Non-covered item or service | 0% | 816 | $0.00 |
| 0346T | 0% | 47 | $0.00 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 26 | $0.00 |
| 91300 | 0% | 323 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLARK, JOHN (VICE PRESIDENT, FINANCE)
Parent organizationREGIONS HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Regions Hospital | Saint Paul, MN | $15.20M |
| Regions Hospital | Saint Paul, MN | $5.62M |
| Regions Hospital | Saint Paul, MN | $4.21M |
| Premier Pediatrics | Alexandria, LA | $2.48M |
| Impact Behavior Health Services LLC. | Harvey, LA | $1.75M |
| Regions Hospital | Saint Paul, MN | $424K |
| Regions Hospital | Coon Rapids, MN | $10K |
| John Nicholas Clark D.D.S., PA | Conway, AR | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.